

A small, scruffy white dog with brown patches around its eyes and ears is sitting on a paved patio. The dog is wearing a green collar with a gold buckle and a blue leash. In the background, a person's legs in khaki pants are visible, sitting on a folding chair. The scene is outdoors with a blurred background of trees and a building.

Credelio®
(lotilaner)

FAST-ACTING TICK AND FLEA CONTROL FOR DOGS AND PUPPIES

PROVEN TO KILL TICKS AND FLEAS



Lotilaner: Chosen out of 1,000 compounds studied

There are plenty of isoxazoline tick and flea medications on the market. You've heard their names. You may have even prescribed some of them to your patients.

WHY LOTILANER:

- Handpicked for its efficacy and safety profile from over 1,000 isoxazoline compounds studied¹
- 100x more powerful in vitro against ticks and fleas than its removed, inactive component¹
- Strongly binds to tick and flea receptors in vitro with no activity on dogs' receptors²

Extra-purified active ingredient¹

An extra purification step is taken for the active ingredient mixture, leaving only the active portion of lotilaner in the final product.

BENEFITS OF EXTRA-PURIFICATION INCLUDE:

- More efficient drug delivery in a small tablet that is easy to give¹
- Less work for the dog or puppy's body to process¹
- Less potential for side effects³

Acts fast against ticks and fleas



2 HOURS

STARTS KILLING TOUGH
LONE STAR TICKS IN JUST
2 HOURS IN A STUDY.⁴

4 HOURS

STARTS KILLING FLEAS IN
JUST 4 HOURS, KILLING FLEAS
BEFORE THEY CAN LAY EGGS.

8 HOURS

KILLS 99.6% OF FLEAS AND 98.7%
OF TICKS* WITHIN 8 HOURS.^{5,6}

*Ixodes ricinus





KILLS TICKS* FAST⁷

Credelio kills *A. Americanum* (lone star ticks) *faster than* NexGard (afoxolaner) and Simparica Trio (sarolaner).⁷

SPEED OF KILL AGAINST *A. AMERICANUM* (LONE STAR TICK)

Day of study	Time point at which product achieved consistent superior efficacy versus untreated control group**		
	Credelio [®] (lotilaner)	Simparica Trio [®] (sarolaner, moxidectin, pyrantel)	Nexgard [®] (afoxolaner)
0	12 HRS	24 HRS	24 HRS
21	12 HRS	48 HRS	48 HRS
28	8 HRS	48 HRS	72 HRS

**P ≤ 0.05
**A. americanum*



WITHIN ONLY 2 HOURS, LONE STAR TICKS SHOWED VAST NEUROMUSCULAR BREAKDOWN, LEADING TO IMPAIRED FEEDING, SALIVARY GLAND DYSFUNCTION AND, ULTIMATELY, DEATH.⁴

Lone star ticks are a challenge

Lone star ticks can be particularly tough to kill, and they are a threat to dogs for several reasons:

- They are highly aggressive, have large mouthparts and actively seek out pets to feed on
- Populations are easily maintained in the wild, and prone to rapid increases in numbers (tick blooms) when favorable conditions arise
- They have expanded their prevalence northward and are no longer considered “southern ticks”




Lotilaner reaches peak absorption in only 2 hours and maintains high, sustained blood levels for the entire month.⁴

HALF-LIFE COMPARISON OF ISOXAZOLINE COMPOUNDS

Brand Name	Isoxazoline compound	5	10	15	20	25	30
Credelio® (lotilaner)	Lotilaner ¹						
Bravecto® (fluralaner) 3-Month Chew	Fluralaner ⁸						
NexGard® (afoxolaner)	Afoxolaner ⁹						
Simparica Trio® (sarolaner, moxidectin, and pyrantel)	Sarolaner ¹⁰						

The clinical significance of half-life data has not been established.

SUPPORTS A FLEA-FREE LIFE FOR DOGS¹²



In a controlled laboratory study, after 24 hours, Credelio completely eliminated flea egg shedding for 30 days.¹¹




By killing biting fleas quickly, Credelio can help relieve flea allergy dermatitis (FAD).^{5,12}



After only one dose, Credelio reduced pruritus and skin lesions with no need for steroids thanks to its fast flea kill.¹²



In a high flea pressure field study based out of Florida, 100% of dogs experienced a reduction in flea infestations after only 2 monthly doses.¹² In a head-to-head study, 100% of dogs were flea-free with Credelio after 3 monthly doses vs. 93.2% with Nexgard.¹³





STUDIES SHOW SUSTAINED EFFICACY AGAINST MULTIPLE SPECIES ALL MONTH LONG¹⁴



CREDELIO PROVIDES A FULL MONTH OF PROTECTION FROM FOUR SPECIES OF TICKS.

	American dog tick	Brown dog tick	Lone Star tick	Black-legged tick
Day	% efficacy	% efficacy	% efficacy	% efficacy
2	100	100	100	100
9	100	100	99	99
16	100	100	100	98
23	100	100	100	100
30	100	100	100	99.6

Credelio kills common ticks that can spread serious diseases in dogs, such as Rocky Mountain spotted fever, ehrlichiosis, babesiosis and Lyme disease.



PROVEN EASY TO ADMINISTER

Delivers 100% administration success¹⁵

Palatability was widely tested in:

- More than 190 dogs
- More than 70 breeds
- Toy breeds (e.g., Chihuahuas, Yorkshire Terriers)
- 567 total doses

Small but mighty











- Small, tasty, monthly chewable
- Shown to be safe for puppies and dogs as small as 4.4 pounds and as young as 8 weeks old



Widely tested with other medications

OVER 150 MEDICATIONS (HEARTWORM PREVENTIVES, STEROIDS, VACCINES AND ANTIBIOTICS, ETC.) HAVE BEEN ADMINISTERED WITH CREDELIO IN STUDIES WITH NO KNOWN CONTRADICTIONS.^{12,16,17}

DOSING: MUST BE ADMINISTERED WITH FOOD

Body weight of dog (lbs)	Tablet strength	Tablet to be administered	Package color	
4.4-6	56.25 mg			Yellow
6.1-12	112.5 mg			Pink
12.1-25	225 mg			Orange
25.1-50	450 mg			Green
50.1-100*	900 mg			Blue

There are no known contraindications
Pills shown are not scaled to size
*For dogs over 100 pounds, prescribe the appropriate combination of tablets to achieve a minimum dose of 9 mg/lb (20 mg/kg).





HELP YOUR PATIENTS OUTRACE TICKS AND FLEAS WITH CREDELIO.

Talk to your Elanco sales Representative today about prescribing Credelio in your clinic.



INDICATIONS

Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of tick infestations [*Amblyomma americanum* (lone star tick), *Dermacentor variabilis* (American dog tick), *Ixodes scapularis* (black-legged tick) and *Rhipicephalus sanguineus* (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater.

IMPORTANT SAFETY INFORMATION

Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio package insert.

REFERENCES

¹Toutain C, Seewald W, Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. *Parasite Vector*. 2017;10:522.

²Rufener L, Danelli V, Bertrand D, et al. The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACs). *Parasite Vector*. 2017;10:530.

³Food and Drug Administration. Development of new stereoisomeric drugs. Available at: <https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122883.htm>. Accessed March 11, 2019.

⁴Elanco Animal Health. Data on file.

⁵Cavalleri D, Murphy M, Seewald W, et al. Assessment of the onset of lotilaner (Credelio™) speed of kill of fleas on dogs. *Parasite Vector*. 2017;10:521.

⁶Murphy M, Cavalleri D, Seewald W, et al. Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against *Ixodes ricinus* ticks on dogs. *Parasite Vector*. 2017;10:541.

⁷Reif KE, Kollasch TM, Neilson JC, et al. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control *Amblyomma americanum* infestations on dogs. *Parasit Vectors*. 2024;17(1):313.

⁸Bravecto prescribing information.

⁹Drag M, Saik J, Harriman J, et al. Safety evaluation of orally administered afoxolaner and milbemycin oxime in eight week old dogs. *J Vet Pharmacol Therap*. 2016;40:447-453.

¹⁰Simparica Trio prescribing information.

¹¹Young L, Karadzovska D, Wiseman S, et al. Efficacy of lotilaner (Credelio®) against the adult cat flea, *Ctenocephalides felis* and flea eggs following oral administration to dogs. *Parasite Vector*. 2020;13:25.

¹²Dryden M, Canfield M, Herrin D, et al. In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida. *Vet Parasitol*. 2019;1:100009.

¹³Karadzovska D, Chappell K, Coble S, et al. A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™) in eliminating fleas in client-owned dogs in the USA. *Parasite Vector*. 2017;10:528.

¹⁴Murphy M, Garcia R, Karadzovska D, et al. Laboratory evaluations of the immediate and sustained efficacy of lotilaner (Credelio™) against four common species of ticks affecting dogs in North America. *Parasite Vector*. 2017;10:523.

¹⁵Elanco Animal Health. Data on file.

¹⁶Cavalleri D, Murphy M, Seewald W, et al. A randomized, controlled study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned dogs in Europe. *Parasite Vector*. 2017;10:531.

¹⁷Cavalleri D, Murphy M, Seewald W, et al. A randomised, blinded, controlled field study to assess the efficacy and safety of lotilaner tablets (Credelio™) in controlling fleas in client owned dogs in European countries. *Parasite Vector*. 2017;10:526.



Credelio™

(lotilaner)

Chewable Tablets

For oral use in dogs

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description:

CREDELIO (lotilaner) is a beef-flavored, chewable tablet for oral administration to dogs and puppies according to their weight. Each chewable tablet is formulated to provide a minimum lotilaner dosage of 9 mg/lb (20 mg/kg).

Lotilaner has the chemical composition of 5-[(5S)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.

Indications:

CREDELIO kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of tick infestations [*Amblyomma americanum* (lone star tick), *Dermacentor variabilis* (American dog tick), *Ixodes scapularis* (black-legged tick) and *Rhipicephalus sanguineus* (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater.

Dosage and Administration:

CREDELIO is given orally once a month, at the minimum dosage of 9 mg/lb (20 mg/kg).

Dosage Schedule:

Body Weight	Lotilaner Per Chewable Tablet (mg)	Chewable Tablets Administered
4.4 to 6.0 lbs	56.25	One
6.1 to 12.0 lbs	112.5	One
12.1 to 25.0 lbs	225	One
25.1 to 50.0 lbs	450	One
50.1 to 100.0 lbs	900	One
Over 100.0 lbs	Administer the appropriate combination of chewable tablets	

CREDELIO must be administered with food (see **Clinical Pharmacology**).

Treatment with CREDELIO can begin at any time of the year and can continue year-round without interruption.

Contraindications:

There are no known contraindications for the use of CREDELIO.

Warnings:

Not for human use. Keep this and all drugs out of the reach of children. Keep CREDELIO in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Precautions:

Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of CREDELIO in breeding, pregnant or lactating dogs has not been evaluated.

Adverse Reactions:

In a well-controlled U.S. field study, which included 284 dogs (198 dogs treated with CREDELIO and 86 dogs treated with an oral active control), there were no serious adverse reactions.

Over the 90-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence of 1% or greater are presented in the following table.

Dogs with Adverse Reactions in the Field Study

Adverse Reaction (AR)	CREDELIO Group: Number (and Percent) of Dogs with the AR (n=198)	Active Control Group: Number (and Percent) of Dogs with the AR (n=86)
Weight Loss	3 (1.5%)	2 (2.3%)
Elevated Blood Urea Nitrogen (BUN)	2 (1.0%)*	0 (0.0%)
Polyuria	2 (1.0%)*	0 (0.0%)
Diarrhea	2 (1.0%)	2 (2.3%)

*Two geriatric dogs developed mildly elevated BUN (34 to 54 mg/dL; reference range: 6 to 31 mg/dL) during the study. One of these dogs also developed polyuria and a mildly elevated potassium (6.5 mEq/L; reference range: 3.6 to 5.5 mEq/L) and phosphorous (6.4 mg/dL; reference range: 2.5 to 6.0 mg/dL). The other dog also developed a mildly elevated creatinine (1.7 to 2.0 mg/dL; reference range: 0.5 to 1.6 mg/dL) and weight loss.

In addition, one dog experienced intermittent head tremors within 1.5 hours of administration of vaccines, an ear cleaning performed by the owner, and its first dose of CREDELIO. The head tremors resolved within 24 hours without treatment. The owner elected to withdraw the dog from the study.

In an Australian field study, one dog with a history of seizures experienced seizure activity (tremors and glazed eyes) six days after receiving CREDELIO. The dog recovered without treatment and completed the study. In the U.S. field study, two dogs with a history of seizures received CREDELIO and experienced no seizures throughout the study.

In three well-controlled European field studies and one U.S. laboratory study, seven dogs experienced episodes of vomiting and four dogs experienced episodes of diarrhea between 6 hours and 3 days after receiving CREDELIO.

Post-Approval Experience (2023):

The following adverse events are based on post-approval adverse drug experience reporting for CREDELIO. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.

The following adverse events reported in dogs are listed in decreasing order of reporting frequency:

Vomiting, diarrhea (with and without blood), lethargy, anorexia, seizure, pruritus, ataxia, urinary-related signs (polyuria, polydipsia, urinary incontinence, and inappropriate urination), and muscle tremor.

Contact Information:

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US Inc. at 1-888-545-5973.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

Clinical Pharmacology:

Following oral administration of 43 mg/kg (approximately 1X the maximum labeled dose), peak lotilaner concentrations were achieved between 6 hours and 3 days in dogs 2 months of age and between 1 and 7 days in dogs 10 months of age. Dogs 2 months of age had a shorter elimination half-life (average of 9.6 days) than at 10 months of age (average of 28.4 days). Due to reduced drug bioavailability in the fasted state, CREDELIO must be administered with a meal or within 30 minutes after feeding.

Mode of Action:

Lotilaner is an ectoparasiticide belonging to the isoxazoline group. Lotilaner inhibits insect and acarine gamma-aminobutyric acid (GABA)-gated chloride channels. This inhibition blocks the transfer of chloride ions across cell membranes, which results in uncontrolled neuromuscular activity leading to death of insects and acarines. The selective toxicity of lotilaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines' GABA receptors versus mammalian GABA receptors.

Effectiveness:

In well-controlled European laboratory studies, CREDELIO began to kill fleas four hours after administration or infestation, with greater than 99% of fleas killed within eight hours after administration or infestation for 35 days. In a well-controlled U.S. laboratory study, CREDELIO demonstrated 100% effectiveness against adult fleas 12 hours after administration or infestation for 35 days.

In a 90-day well-controlled U.S. field study conducted in households with existing flea infestations of varying severity, the effectiveness of CREDELIO against fleas on Days 30, 60 and 90 compared to baseline was 99.5%, 100% and 100%, respectively. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermitis and pruritus as a direct result of eliminating fleas.

In a well-controlled laboratory study, CREDELIO killed fleas before they could lay eggs, thus preventing subsequent flea infestations for 30 days after the start of treatment of existing flea infestations.

In well-controlled laboratory studies, CREDELIO demonstrated > 97% effectiveness against *Amblyomma americanum*, *Dermacentor variabilis*, *Ixodes scapularis* and *Rhipicephalus sanguineus* ticks 48 hours after administration or infestation for 30 days. In a well-controlled European laboratory study, CREDELIO started killing *Ixodes ricinus* ticks within four hours after administration.

Palatability: In the U.S. field study, which included 567 doses administered to 198 dogs, 80.4% of dogs voluntarily consumed CREDELIO when offered by hand or in an empty bowl, an additional 13.6% consumed CREDELIO when offered with food, and 6.0% required placement of the chewable tablet in the back of the dog's mouth.

Animal Safety:

In a margin of safety study, CREDELIO was administered orally to 24 (8 dogs/group) 8-week-old Beagle puppies at doses of 43 mg/kg, 129 mg/kg, and 215 mg/kg (approximately 1, 3, and 5X the maximum labeled dose, respectively) every 28 days for eight consecutive doses. The 8 dogs in the control group (0X) were untreated. There were no clinically-relevant, treatment-related effects on clinical observations, physical and neurological examinations, body weights, food consumption, electrocardiograms, clinical pathology (hematology, clinical chemistries, coagulation profiles and urinalysis), gross pathology, histopathology, or organ weights. Blood concentrations of lotilaner confirmed systemic exposure of all treated dogs, although the exposure was less than dose proportional at 5X.

In a well-controlled field study, CREDELIO was used concurrently with other medications, such as vaccines, anthelmintics, antibiotics, steroids, NSAIDs, anesthetics, and antihistamines. No adverse reactions were observed from the concomitant use of CREDELIO with other medications.

Storage Information:

Store at 15-25°C (59 - 77°F), excursions permitted between 5 to 40°C (41 to 104°F).

How Supplied:

CREDELIO is available in five chewable tablet sizes for use in dogs: 56.25, 112.5, 225, 450, and 900 mg lotilaner.

Each chewable tablet size is available in color-coded packages of 1, 3 or 6 chewable tablets.

Approved by FDA under NADA # 141-494

Manufactured for:

Elanco US Inc
Greenfield, IN 46140 USA
Credelio.com
Rev. date 02/2024

Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
© 2024 Elanco or its affiliates

